Formycon AG (FYB)

Currency in EUR
30.65
+0.60(+2.00%)
Delayed Data·
FYB Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
FYB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
30.1530.75
52 wk Range
18.6263.70
Key Statistics
Bid/Ask
30.50 / 30.60
Prev. Close
30.05
Open
30.15
Day's Range
30.15-30.75
52 wk Range
18.62-63.7
Volume
137
Average Volume (3m)
382
1-Year Change
-40.02%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FYB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Formycon AG News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Formycon AG Company Profile

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, hodgkin’s lymphoma, urothelial carcinomas, tumors in the head and neck area, other tumor diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Compare FYB to Peers and Sector

Metrics to compare
FYB
Peers
Sector
Relationship
P/E Ratio
−4.2x−1.1x−0.5x
PEG Ratio
0.020.150.00
Price/Book
1.1x1.1x2.6x
Price / LTM Sales
7.6x4.6x3.2x
Upside (Analyst Target)
54.4%143.2%40.5%
Fair Value Upside
Unlock5.3%4.4%Unlock

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.85 / -0.04
Revenue / Forecast
5.30M / 16.00M
EPS Revisions
Last 90 days

FYB Income Statement

People Also Watch

26.76
CNC
-9.04%
200.82
IQV
+3.39%
20.420
NDXG
-0.58%
97.25
HAGG
+0.31%
28.160
FNTGn
-0.42%

FAQ

What Stock Exchange Does Formycon AG Trade On?

Formycon AG is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Formycon AG?

The stock symbol for Formycon AG is "FYB."

What Is the Formycon AG Market Cap?

As of today, Formycon AG market cap is 540.30M.

What Is Formycon AG's Earnings Per Share (TTM)?

The Formycon AG EPS (TTM) is -7.18.

When Is the Next Formycon AG Earnings Date?

Formycon AG will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is FYB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Formycon AG Stock Split?

Formycon AG has split 3 times.

How Many Employees Does Formycon AG Have?

Formycon AG has 250 employees.

What is the current trading status of Formycon AG (FYB)?

As of 25 Jul 2025, Formycon AG (FYB) is trading at a price of 30.65, with a previous close of 30.05. The stock has fluctuated within a day range of 30.15 to 30.75, while its 52-week range spans from 18.62 to 63.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.